William Blair initiated coverage of McKesson (MCK) with an Outperform rating. The company has a “durable competitive moat” with specialty-led growth upside, the analyst tells investors in a research note. The firm believes McKesson is positioned to capitalize on a structurally favorable demand backdrop supported by demographic tailwinds and rising adoption of specialty medicines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- The Week That Was, The Week Ahead: Macro and Markets, April 26
- McKesson price target lowered to $1,000 from $1,012 at UBS
- Apollo Funds to invest $1.25B to acquire 13% interest in McKesson’s MMS business
- McKesson target cut, added to ‘Tactical Underperform’ list at Evercore ISI
- McKesson Secures New $2 Billion Senior Credit Facilities